{"protocolSection":{"identificationModule":{"nctId":"NCT04952064","orgStudyIdInfo":{"id":"Y（2021）052"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke","officialTitle":"Ganglioside GM1 in Acute Ischemic Stroke: a Prospective, Randomized, Blinded Assessment of Endpoints, and Multicenter Exploratory Study"},"statusModule":{"statusVerifiedDate":"2022-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-07-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-07-18","type":"ACTUAL"},"completionDateStruct":{"date":"2022-07-18","type":"ACTUAL"},"studyFirstSubmitDate":"2021-06-30","studyFirstSubmitQcDate":"2021-06-30","studyFirstPostDateStruct":{"date":"2021-07-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-09-22","lastUpdatePostDateStruct":{"date":"2022-09-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Professor","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"General Hospital of Shenyang Military Region","class":"OTHER"},"collaborators":[{"name":"The Third Xiangya Hospital of Central South University","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study was to evaluate the efficacy and safety of higher doses of monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke."},"conditionsModule":{"conditions":["Stroke, Ischemic"],"keywords":["monosialoganglioside GM1","Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":300,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"200 mg group","type":"EXPERIMENTAL","description":"Monosialoganglioside GM1, 200 mg/day, for 12-14 days","interventionNames":["Drug: Monosialoganglioside GM1"]},{"label":"400 mg group","type":"EXPERIMENTAL","description":"Monosialoganglioside GM1, 400 mg/day, for 12-14 days","interventionNames":["Drug: Monosialoganglioside GM1"]}],"interventions":[{"type":"DRUG","name":"Monosialoganglioside GM1","description":"Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days","armGroupLabels":["200 mg group","400 mg group"],"otherNames":["GM1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of modified Rankin Scale (mRS) 0-2","description":"the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Proportion of modified Rankin Scale (mRS) 0-1","description":"the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome","timeFrame":"90 days"},{"measure":"changes in National Institute of Health stroke scale","description":"the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome","timeFrame":"7 days and 14 days"},{"measure":"changes in Barthel index (BI) scale","description":"the minimum and maximum values of BI are 0 and 100, respectively; higher BI mean a good outcome","timeFrame":"30 days and 90 days"}],"otherOutcomes":[{"measure":"changes in some serum biomarkers","description":"serum biomarkers included SOD，BDNF，NGF，CRP，TNF-α，IL-6，IL-1β，VEGF，NO，MMP","timeFrame":"7 days and 14 days"},{"measure":"The change of infarct volume","description":"The change of infarct volume showed by MRI compared with baseline","timeFrame":"3 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1. Age: 18-80 years old；\n* 2. Patients with anterior circulation cerebral infarction;\n* 3. first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)；\n* 4. Within 24 hours of onset；\n* 5. 5 ≤NIHSS score ≤ 20；\n* 6. Signed informed consent.\n\nExclusion Criteria:\n\n* 1. Patients with hereditary abnormal glucose and lipid metabolism (gangliosidosis, such as Tay-Sachs disease and retinal degeneration);\n* 2. Hemorrhagic stroke;\n* 3. Disturbance of consciousness (NIHSS1a≥1)，or cerebral arteritis, brain tumor, brain trauma, intracranial infectious diseases;\n* 4. Planed endovascular treatment;\n* 5. Uncontrolled hypertension: systolic pressure ≥200 mmHg or diastolic pressure ≥110 mmHg;\n* 6. Bleeding tendency (except for thrombolysis) or severe bleeding within 3 months;\n* 7. Patients with malignant tumor or serious diseases;\n* 8. Along with epilepsy, arthritis and other disease, which have effect on neurological assessment;\n* 9. History of autoimmune diseases, spinal trauma, various demyelinating diseases, including acute inflammatory demyelinating polyneuropathy (Guillain Barre syndrome);\n* 10. Unable or unwilling to cooperate due to mental diseases;\n* 11. Abnormal liver and renal function: ALT, AST \\> 2 times of the upper limit of normal value, or Cr \\> 1.5 times of the upper limit of normal value；\n* 12. Hypersensitivity to monosialoganglioside and excipients of test drug;\n* 13. History of drug abuse；\n* 14. Pregnant or lactating women, pregnant plan or unwilling to use effective contraception during the trial period;\n* 15. Participating in other clinical trials within 3 months;\n* 16. Other conditions which are unsuitable for this trial assessed by researcher.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Chen Huisheng, Doctor","affiliation":"General Hospital of Shenyang Military Region","role":"STUDY_CHAIR"}],"locations":[{"facility":"General Hospital of ShenYang Military Region","city":"Shenyang","state":"Liaoning","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}